Skip to main content
Retour
Watch Compare

Bolt Biotherapeutics, Inc.

Qualité des données : 100%
BOLT
NASDAQ Manufacturing Chemicals
4,91 €
▲ 0,40 € (8,87%)
Cap. Boursière: 8,67 M
Prix
4,51 €
Cap. Boursière
8,67 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue grew 57,20% annually over 5 years — strong growth
Negative free cash flow of -39,92 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 57,13%
Capital efficient — spends only 0,94% of revenue on capex

Croissance

Revenue Growth (5Y)
57,20%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)0,07%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-94,09%
En dessous de la moyenne du secteur (-54,01%)
ROIC-48,24%
Net Margin-433,74%
Op. Margin-469,30%

Sécurité

Debt / Equity
N/A
Current Ratio3,57
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-0,26 | -0,20
Au-dessus de la moyenne du secteur (-1,49)
P/B Ratio0,27
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1385 pairs)
Métrique Action Médiane du Secteur
P/E -0,3 -1,5
P/B 0,3 1,6
ROE % -94,1 -54,0
Net Margin % -433,7 -41,5
Rev Growth 5Y % 57,2 1,8
D/E — 0,3

Objectif de Cours des Analystes

3 analystes
Buy
Actuel
4,91 €
+490.6%
Objectif
29,00 €
5,00 €
7,00 €
75,00 €
Prévisions
P/E Prévisionnel -0,20
BPA Prévisionnel -24,74 €
CA Est. 3,50 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -24,74 €
-24,74 € – -24,74 €
 3,50 M 1
FY2026 -34,30 €
-34,30 € – -34,30 €
 2,33 M 1

Surprises de Résultats

Derniers 4 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -5,52 € -2,98 € +46,0%
Q32025 -5,40 € -3,72 € +31,1%
Q22025 -6,27 € -4,46 € +28,8%
Q12025 -7,20 € -5,80 € +19,4%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,07% Revenue Growth (3Y) -1,16%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 57,20% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 7,70 M Net Income (TTM) -33,38 M
ROE -94,09% ROA -47,49%
Gross Margin N/A Operating Margin -469,30%
Net Margin -433,74% Free Cash Flow (TTM) -39,92 M
ROIC -48,24% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,57
Interest Coverage N/A Asset Turnover 0,11
Working Capital 25,64 M Tangible Book Value 32,10 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,26 Forward P/E -0,20
P/B Ratio 0,27 P/S Ratio 1,13
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2,48 Fwd Earnings Yield N/A
FCF Yield -460,66%
Market Cap 8,67 M Enterprise Value -9,09 M
Per Share
EPS (Diluted TTM) -17,85 Revenue / Share 4,00
FCF / Share -20,78 OCF / Share -20,74
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,94% FCF Conversion 119,61%
SBC-Adj. FCF -42,76 M Growth Momentum -57,13

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 7,70 M 7,69 M 7,88 M 5,73 M 1,26 M
Net Income -33,38 M -63,12 M -69,20 M -88,10 M -98,59 M
EPS (Diluted) -17,85 -1,65 -1,83 -2,36 —
Gross Profit — — — — —
Operating Income -36,11 M -73,05 M -76,20 M -90,32 M -92,79 M
EBITDA — — — — —
R&D Expenses 28,53 M 57,47 M 61,54 M 73,12 M 75,66 M
SG&A Expenses — — — — —
D&A 1,29 M 1,78 M 1,85 M 1,67 M 1,19 M
Interest Expense — — — — —
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 56,75 M 99,63 M 159,78 M 227,81 M 307,72 M
Total Liabilities 30,24 M 42,43 M 47,04 M 56,30 M 57,60 M
Shareholders' Equity 26,51 M 57,20 M 112,74 M 171,51 M 250,12 M
Total Debt — — — — —
Cash & Equivalents 11,70 M 7,21 M 10,81 M 9,24 M 27,38 M
Current Assets 30,26 M 50,81 M 105,71 M 172,75 M 189,16 M
Current Liabilities 8,44 M 15,86 M 20,46 M 23,12 M 21,33 M